| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/22/2009 | US20090023638 Spill resistant antibiotic formulations |
| 01/22/2009 | US20090023637 Methods for detecting and treating interstitial cystitis |
| 01/22/2009 | US20090023636 Methods and compositions for the prevention and treatment of anemia |
| 01/22/2009 | US20090023635 Factor VII or VIIa - Like Molecules |
| 01/22/2009 | US20090023634 Regulation of mineral and skeletal metabolism |
| 01/22/2009 | US20090023633 Regulation of mineral and skeletal metabolism |
| 01/22/2009 | US20090023632 Hemoglobin-haptoglobin complexes |
| 01/22/2009 | US20090023631 Composition and Method of Use for Soft Tissue Augmentation/Drug Delivery |
| 01/22/2009 | US20090023630 Methods and Means for Use in Diagnostics and Treatment of Diabetes |
| 01/22/2009 | US20090023629 Compositions comprising polycation-complexed protein crystals and methods of treatment using them |
| 01/22/2009 | US20090023628 Cosmetic Composition and a Process for Preparing This Cosmetic Composition and a Cosmetic Product |
| 01/22/2009 | US20090023627 Compositions and methods for alzheimer's disease |
| 01/22/2009 | US20090023226 Variant Integrin Polypeptides and Uses Thereof |
| 01/22/2009 | US20090023224 Vascular endothelial growth factor 2 |
| 01/22/2009 | US20090023207 CHROMOSOME 3p21.3 GENES ARE TUMOR SUPPRESSORS |
| 01/22/2009 | US20090023184 Novel Tachykinin Peptides, Precursor Peptides Thereof And Genes Encoding The Same |
| 01/22/2009 | US20090023169 High throughput sarcomeric assay |
| 01/22/2009 | US20090023160 Antibodies specific for CYP1B1 |
| 01/22/2009 | US20090023152 Transcription factor MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substances |
| 01/22/2009 | US20090023147 Diagnostics and therapeutics for osteoporosis |
| 01/22/2009 | US20090023145 Methods of diagnosing or prognosing Alzheimer's disease |
| 01/22/2009 | US20090022831 Use of fructus schisandrae and extracts thereof in preventing and decreasing toxic and side effects of antineoplastic drugs |
| 01/22/2009 | US20090022826 Multi-step method of pain and/or inflammation treatment |
| 01/22/2009 | US20090022823 Methods for Administering Active Agents to CYP3A4 Sensitive Patients |
| 01/22/2009 | US20090022813 Composition for improving membrane composition and functioning of cells |
| 01/22/2009 | US20090022802 Cardiomyopathy therapeutic agent |
| 01/22/2009 | US20090022801 Compositions and Methods for Promoting the Healing of Tissue of Multicellular Organisms |
| 01/22/2009 | US20090022784 Systems, devices, and methods for iontophoretic delivery of compositions including liposome-encapsulated insulin |
| 01/22/2009 | US20090022777 Methods for progenitor cell recruitment and isolation |
| 01/22/2009 | US20090022776 Composition and method for treatment and prevention of restenosis |
| 01/22/2009 | US20090022748 Unique associated Kaposi's sarcoma virus sequences and uses thereof |
| 01/22/2009 | US20090022743 Peptides Effective in the Treatment of Tumors and Other Conditions Requiring the Removal or Destruction of Cells |
| 01/22/2009 | US20090022742 Compounds and methods for diagnosis and immunotherapy of tuberculosis |
| 01/22/2009 | US20090022741 Targetting slow-growing, relatively mutationally-spared cancer; one-step genetic switches; antiproliferative agents; magnetic resonance imaging |
| 01/22/2009 | US20090022740 Targetting slow-growing, relatively mutationally-spared cancer; one-step genetic switches; antiproliferative agents; magnetic resonance imaging |
| 01/22/2009 | US20090022739 MODULATING THE KV1.1 VOLTAGE-GATED POTASSIUM CHANNEL IN T-CELLS FOR REGULATING THE SYNTHESIS AND SECRETION OF TUMOR NECROSIS FACTOR ALPHA (tnf-ALPHA) AND TREATING HUMAN DISEASE OR INJURIES MEDIATED BY DETRIMENTALLY HIGH OR LOW LEVELS OF TNF-ALPHA |
| 01/22/2009 | US20090022737 Aldos as modifiers of the igf pathway and methods of use |
| 01/22/2009 | US20090022734 Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis |
| 01/22/2009 | US20090022733 Methods for treating Disease with an IL-1R antibody |
| 01/22/2009 | US20090022729 Methods and compositions for treating cardiac dysfunctions |
| 01/22/2009 | US20090022725 antagonist antibody that blocks binding of IL-17; degenerative cartilaginous disorders and other inflammatory diseases |
| 01/22/2009 | US20090022724 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 01/22/2009 | US20090022719 Preventive and/or therapeutic method for systemic lupus erythematosus comprising anti-IL-6 receptor antibody administration |
| 01/22/2009 | US20090022718 Methods of treating a blood pathology using anti-TNF antibodies and fragments thereof |
| 01/22/2009 | US20090022716 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 01/22/2009 | US20090022714 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 01/22/2009 | US20090022713 Anti-pro87299 antibodies |
| 01/22/2009 | US20090022712 Compositions and Methods for Inhibiting Leukocyte Function |
| 01/22/2009 | US20090022711 Methods of modulating cell death based on the bit-1/aes regulatory pathway |
| 01/22/2009 | US20090022710 Nuclear factor of activated t cells receptor |
| 01/22/2009 | US20090022708 Trefoil Factors and Methods of Treating Proliferation Disorders Using Same |
| 01/22/2009 | US20090022706 Substituted cyclohexenes |
| 01/22/2009 | US20090022705 Chloroplasts engineered to express pharmaceutical proteins in edible plants |
| 01/22/2009 | US20090022704 Method for the treatment of gout or pseudogout |
| 01/22/2009 | US20090022703 Treating age-related macular degeneration associated with a loss of elastic fibers by administering a LOXL1 polypeptide that can catalyze the crosslinking of elastin |
| 01/22/2009 | US20090022702 Methods for introducing mannose 6-phosphate and other oligosacharides onto glycoproteins |
| 01/22/2009 | US20090022701 Administering to the patient an amount of CLN2 protein (Neuronal ceroid lipofuscinoses (NCLs)) effective to reduce or eliminate the symptoms caused by the deficiencyl in CLN2 protein; Central nervous system disorders |
| 01/22/2009 | US20090022689 C4-spiro-pyrrolidine antivirals |
| 01/22/2009 | US20090022688 Inhibitors of serine protease, particularly hcv ns3-ns4a protease |
| 01/22/2009 | US20090022687 Novel Pharmaceuticals That Use Anti-HLA Antibodies |
| 01/22/2009 | US20090022686 Pharmaceutical compositions for the treatment of systemic inflammatory response syndrome |
| 01/22/2009 | US20090022685 Orthotopic, controllable, and genetically tractable non-human animal model for cancer |
| 01/22/2009 | US20090022684 Methods for hematopoietic stimulation |
| 01/22/2009 | US20090022683 Biodegradable and Thermosensitive Poly(Organophosphazene) Hydrogel, Preparation Method Thereof and Use Thereof |
| 01/22/2009 | US20090022673 Composition and packaging method for animal dental care |
| 01/22/2009 | US20090022669 Compositions for protein delivery via the pulmonary route |
| 01/22/2009 | US20090022657 Novel CXCL8 antagonists |
| 01/22/2009 | US20090022656 Lipidated glycoprotein particles and methods of use |
| 01/22/2009 | CA2789123A1 Insulinotropic peptide derivative wherein its n-terminal amino acid is modified |
| 01/22/2009 | CA2789112A1 Insulinotropic peptide derivative wherein its n-terminal amino acid is modified |
| 01/22/2009 | CA2730841A1 Osteopontin nanoparticle system for drug delivery |
| 01/22/2009 | CA2700477A1 Method for reducing intracranial pressure |
| 01/22/2009 | CA2699891A1 Macrocyclic compounds as antiviral agents |
| 01/22/2009 | CA2696833A1 Disease treatment via antimicrobial peptides or their inhibitors |
| 01/22/2009 | CA2694983A1 Treatments of b-cell proliferative disorders |
| 01/22/2009 | CA2694011A1 Survivin peptides as cancer vaccines |
| 01/22/2009 | CA2693862A1 Specific therapy and medicament using integrin ligands for treating cancer |
| 01/22/2009 | CA2693219A1 Compositions and methods for wound healing |
| 01/22/2009 | CA2693141A1 Use of a granulin or a granulin-like compound for the therapy or prophylaxis of chronic pain |
| 01/22/2009 | CA2693051A1 Lantibiotic-based compounds having antimicrobial activity |
| 01/22/2009 | CA2693047A1 The use of type-b lantibiotic-based compounds having antimicrobial activity |
| 01/22/2009 | CA2692612A1 Purification of pegylated polypeptides |
| 01/22/2009 | CA2691406A1 Preprocalcitonin antigen t epitopes |
| 01/22/2009 | CA2691127A1 Phosphorylation of histone h3 at threonine 11 - a novel epigenetic mark for transcriptional regulation |
| 01/21/2009 | EP2017621A1 Phosphorylation of histone H3 at threonine 11 - a novel epigenetic mark for transcriptional regulation |
| 01/21/2009 | EP2017617A1 Wound dressing |
| 01/21/2009 | EP2017343A2 Protein A based binding domains with desirable activities |
| 01/21/2009 | EP2017342A1 Recombinant allergen with reduced enzymatic activity |
| 01/21/2009 | EP2017341A2 Apo-2 ligand |
| 01/21/2009 | EP2017338A1 Muscle-specific expression vectors |
| 01/21/2009 | EP2017337A1 Human tumor necrosis factor receptors |
| 01/21/2009 | EP2017288A1 Protease stabilized, pegylated insulin analogues |
| 01/21/2009 | EP2017287A2 Method of producing hydroxyalkyl starch derivatives |
| 01/21/2009 | EP2017285A1 Antimicrobial linear peptides |
| 01/21/2009 | EP2017284A1 New polypeptides inducing apoptosis and uses thereof |
| 01/21/2009 | EP2017283A1 Peptide |
| 01/21/2009 | EP2016953A2 Vascular endothelial cell growth factor antagonists and uses thereof |
| 01/21/2009 | EP2016952A2 A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| 01/21/2009 | EP2016951A1 Polypeptides homologous to VEGF and BMP1 |
| 01/21/2009 | EP2016950A1 Pharmaceutical composition comprising an exedin-4 peptide |